TABLE 3

Summary of calculated pharmacokinetic parameters fixed in PBPK analyses

If not indicated, pharmacokinetic parameters were derived from the University of Washington Metabolism and Transport Drug Interaction Database (DIDB).

CompoundKp,haFaFgRBfBReferences (PubMed ID)
Substrates
 Chlorpromazine-b0.6850.7810534321,c
 Desipramine-b1.03d0.893365915
 Fentanyl-b1e6121896
 Flurbiprofen-b>1d0.56f
 Hydrocodone-b1e1e
 Imipramine-b0.971.16429693, 10534321
 Lansoprazole-b1.97d0.568803522, 20056146
 Losartan-b0.8960.6g8529329
 Omeprazole-b1.83d0.583858978
 Oxycodone-b1.05d1.319417618, 22798176
 Ropivacaine-b0.6911322176
Inhibitors
 Fluconazole0.647-b10.8918483837
 Fluoxetine13.60.7220.960.06318483837
 Fluvoxamine12.10.97110.2318483837
 Itraconazole6.380.8850.580.06218483837, 17495874
 Quinidine11.60.8690.920.1418483837
 Voriconazole0.56211e0.42
  • FaFg, intestinal availability; RB, blood-to-plasma concentration ratio.

  • a Predicted with the reported in silico methods (Rodgers et al., 2005; Rodgers and Rowland, 2006).

  • b Estimated in the following PBPK analysis.

  • c Thummel et al. 2010.

  • d FaFg calculated to be >1 was fixed as 1 for PBPK analysis.

  • e Assumed to be equal to 1.

  • f Tono et al. 1992.

  • g Assumed to be equal to 0.6.